Gastroenterology Research, ISSN 1918-2805 print, 1918-2813 online, Open Access
Article copyright, the authors; Journal compilation copyright, Gastroenterol Res and Elmer Press Inc
Journal website https://www.gastrores.org

Short Communication

Volume 14, Number 3, June 2021, pages 190-193


Pre-Transplant Factors Influencing Rates of Hepatocellular Carcinoma Recurrence in Liver Transplant Recipients

Tables

Table 1. Pre-transplant HCC Information for the Recurrent and Non-Recurrent Cohorts
 
HCC pre-transplant informationNon-recurrent (n = 123)Recurrent (n = 9)P value
Means (with standard deviation for continuous values, column percentages for ordinal/categorical variables) for each cohort represented, as well as P values for statistical significance between the cohorts. HCC: hepatocellular carcinoma; MELD: model for end-stage liver disease; AFP: alpha fetoprotein; TACE: transcatheter arterial chemoembolization.
Interval (days) between HCC diagnosis and transplant503.5 ± 384.9847.1 ± 635.80.015
Interval (days) between listing and transplant224.9 ± 206.0341.1 ± 190.30.103
MELD at diagnosis11.9 ± 6.211.2 ± 4.90.745
AFP at diagnosis220.6 ± 1,351.444.4 ± 105.20.698
Initial tumor number1.4 ± 0.71.7 ± 0.70.312
Largest tumor measurement (cm)2.9 ± 1.23.1 ± 1.40.576
Full Milan criteria104 (87%)7 (78%)0.412
Treatment modality
  Surgical resection1 (1%)1 (11%)0.015
  Ablation34 (28%)6 (67%)0.014
  Rounds of ablation1.3 ± 0.81.5 ± 0.80.509
  TACE87 (71%)7 (78%)0.652
  Rounds of TACE1.4 ± 0.71.9 ± 0.90.072
  Radiation32 (26%)5 (56%)0.057
  Rounds of radiation1.1 ± 0.31.6 ± 0.50.011
  Chemotherapy2 (2%)-0.700
  Total number of treatments pre-transplant1.6 ± 1.03.6 ± 1.8< 0.001
Lobe involved
  Left21 (17%)1 (11%)0.643
  Right97 (79%)7 (78%)0.939
  Quadrate15 (12%)-0.266
  Caudate5 (4%)2 (22%)0.019

 

Table 2. Post-Transplant Outcomes and Complications for the Recurrent and Non-Recurrent Cohorts
 
Outcomes/complicationsNon-recurrent (n = 123)Recurrent (n = 9)P value
Means (with percentages for ordinal/categorical variables) for each cohort represented, as well as P values for statistical significance between the cohorts. HAS: hepatic artery stenosis; HAT: hepatic artery thrombosis; DVT: deep venous thrombosis.
HAS24 (20%)4 (44%)0.077
HAT10 (8%)-0.371
Biliary leak6 (5%)-0.496
Biliary stricture21 (17%)-0.174
DVT6 (5%)2 (22%)0.035
Reexploration13 (11%)1 (11%)0.959
Graft rejection19 (15%)3 (33%)0.165
Graft failure12 (10%)1 (11%)0.895
Retransplant5 (42%)0 (%)0.411
Death19 (15%)8 (89%)< 0.001